- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
RFA joins arsenal for breast cancer metastases in the liver
In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.
In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.
Researchers from 12 centers participating in the tumor radio-frequency ablation Italian network (TRAIN) treated 102 patients with breast cancer, using the ablation technique. Under ultrasound or CT guidance, they applied RFA to tumors ranging from 0.8 to 5 cm in diameter. Results were presented at the 2004 RSNA meeting.
Using the Kaplan-Meier method, the researchers reported survival rates ranging from 95.2% at one year to 29.8% at five years. They completed RFA of tumors in 91.2% of the patients after 121 treatment sessions, and the primary effectiveness rate on a lesion-by-lesion basis was 86.9.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
